- Home
- MED vs CRBU Comparison
MED vs CRBU Comparison
Compare MED & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- CRBU
- Stock Information
- Founded
- MED 1980
- CRBU 2011
- Country
- MED United States
- CRBU United States
- Employees
- MED N/A
- CRBU N/A
- Industry
- MED Packaged Foods
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- MED Consumer Staples
- CRBU Health Care
- Exchange
- MED Nasdaq
- CRBU Nasdaq
- Market Cap
- MED 201.4M
- CRBU 236.3M
- IPO Year
- MED N/A
- CRBU 2021
- Fundamental
- Price
- MED $16.88
- CRBU $1.79
- Analyst Decision
- MED Hold
- CRBU Strong Buy
- Analyst Count
- MED 1
- CRBU 4
- Target Price
- MED $17.00
- CRBU $12.00
- AVG Volume (30 Days)
- MED 246.0K
- CRBU 1.5M
- Earning Date
- MED 11-04-2024
- CRBU 11-06-2024
- Dividend Yield
- MED N/A
- CRBU N/A
- EPS Growth
- MED N/A
- CRBU N/A
- EPS
- MED 0.67
- CRBU N/A
- Revenue
- MED $674,475,000.00
- CRBU $11,475,000.00
- Revenue This Year
- MED N/A
- CRBU N/A
- Revenue Next Year
- MED N/A
- CRBU N/A
- P/E Ratio
- MED $25.42
- CRBU N/A
- Revenue Growth
- MED N/A
- CRBU N/A
- 52 Week Low
- MED $16.73
- CRBU $1.50
- 52 Week High
- MED $70.58
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- MED 36.65
- CRBU 37.96
- Support Level
- MED $17.69
- CRBU $1.72
- Resistance Level
- MED $21.98
- CRBU $1.97
- Average True Range (ATR)
- MED 1.17
- CRBU 0.14
- MACD
- MED -0.39
- CRBU -0.03
- Stochastic Oscillator
- MED 2.90
- CRBU 9.12
About MED MEDIFAST INC
Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.